Clinical Briefs
Patient Assessment After Possible Recalled Tyenne Exposure
An FDA-posted recall covers an affected lot of tocilizumab-aazg (Tyenne) vials because of possible glass particles. Clinicians should separate patient assessment from inventory control.
Rayan Salih · September 10, 2026 · 6 min